3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Urinary Bladder, Neurogenic
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Malnutrition
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Etoposide
34
Carboplatin
31
Topotecan
24
Cisplatin
21
atezolizumab
11
PM 01183
8
durvalumab
7
Irinotecan
7
amrubicin
5
PE regimen
4
AMG 757
4
rovalpituzumab tesirine
3
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Dexamethasone
3
tremelimumab
2
tislelizumab
2
etoposide phosphate
2
apatinib
2
Vitamin E
2
Tiragolumab
2
Specimen Handling
2
Radiosurgery
2
RRx-001
2
Paclitaxel
2
Memantine
2
Injections
2
EC regimen
2
trilaciclib
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Small Cell Lung Carcinoma
×
Immunonutrition Diet
×
Clear all
NCT06840704
2026-04-02
Relief
Hunan Cancer Hospital
Phase 3
Recruiting
121 enrolled